Xeris Biopharma Holdings (XERS) Long-Term Investments (2020 - 2021)
Xeris Biopharma Holdings' (XERS) quarterly Long-Term Investments came in at $33.5 million in Q3 2021, down 65.18% on a QoQ basis from $96.2 million in Q4 2020.
Xeris Biopharma Holdings (XERS) Long-Term Investments (2020 - 2021) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 2 years of Long-Term Investments data on file, last reported at $33.5 million in Q3 2021.
- Quarterly Long-Term Investments changed N/A year-over-year to $33.5 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $33.5 million (changed N/A YoY) and the FY2020 annual result came in at $96.2 million, changed N/A from the prior year.
- Long-Term Investments retreated to $33.5 million in Q3 2021, from $96.2 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $96.2 million in Q4 2020 to a low of $33.5 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 92.58 Mn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 63.23 Mn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 1.14 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 149.10 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 60.00 Mn |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 33.49 Mn |
| Dec 31, 2020 | 96.19 Mn |